ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 567,98
0,57%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Amgen Inc (AMGN)

  7. Amgen Inc (AMGN) Actualités

AMGN

Amgen (AMGN)

Amgen Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AMGN
DateHeureSourceTitreSymboleSociété
14/06/202422h21PR Newswire (US)FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASENASDAQ:AMGNAmgen Inc
12/06/202423h23Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AMGNAmgen Inc
12/06/202415h00PR Newswire (US)AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024NASDAQ:AMGNAmgen Inc
05/06/202422h00PR Newswire (US)AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCENASDAQ:AMGNAmgen Inc
05/06/202415h00PR Newswire (US)AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)NASDAQ:AMGNAmgen Inc
05/06/202401h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
05/06/202401h22Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
03/06/202423h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMGNAmgen Inc
03/06/202422h00PR Newswire (US)AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCENASDAQ:AMGNAmgen Inc
28/05/202415h00PR Newswire (US)AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024NASDAQ:AMGNAmgen Inc
19/05/202423h15PR Newswire (US)NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPDNASDAQ:AMGNAmgen Inc
17/05/202400h46PR Newswire (US)FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCERNASDAQ:AMGNAmgen Inc
16/05/202400h45PR Newswire (US)AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024NASDAQ:AMGNAmgen Inc
10/05/202422h02Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AMGNAmgen Inc
09/05/202422h00PR Newswire (US)AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCENASDAQ:AMGNAmgen Inc
03/05/202415h12IH Market NewsAmgen, Bock Up; Cloudflare, Expedia WeakNASDAQ:AMGNAmgen Inc
02/05/202422h01PR Newswire (US)AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTSNASDAQ:AMGNAmgen Inc
01/05/202413h00PR Newswire (US)AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024NASDAQ:AMGNAmgen Inc
29/04/202422h00PR Newswire (US)AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTSNASDAQ:AMGNAmgen Inc
26/04/202415h00PR Newswire (US)AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCYNASDAQ:AMGNAmgen Inc
16/04/202423h26PR Newswire (US)AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024NASDAQ:AMGNAmgen Inc
09/03/202418h20PR Newswire (US)AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024NASDAQ:AMGNAmgen Inc
06/03/202422h00PR Newswire (US)AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDENDNASDAQ:AMGNAmgen Inc
29/02/202422h00PR Newswire (US)AMGEN TO PRESENT AT THE 44TH ANNUAL TD COWEN HEALTH CARE CONFERENCENASDAQ:AMGNAmgen Inc
26/02/202415h00PR Newswire (US)AMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIONASDAQ:AMGNAmgen Inc
19/02/202422h00PR Newswire (US)AMGEN TO HOST CONFERENCE CALL ON RARE DISEASENASDAQ:AMGNAmgen Inc
14/02/202422h23Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AMGNAmgen Inc
09/02/202422h00PR Newswire (US)AMGEN TO PRESENT AT THE 34TH ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCENASDAQ:AMGNAmgen Inc
07/02/202411h49IH Market NewsMoody’s Downgrades NYCB to Junk Status, Ford Declares Special Dividend, and Other Market UpdatesNASDAQ:AMGNAmgen Inc
06/02/202423h05IH Market NewsU.S. Stocks Finish Choppy Trading Day Modestly HigherNASDAQ:AMGNAmgen Inc
 Showing the most relevant articles for your search:NASDAQ:AMGN

Dernières Valeurs Consultées

EU
DG
Vinci
EU
AF
Air FranceKLM
NASDAQ
NVDA
NVIDIA
EU
ACA
Credit Agricole
NASDAQ
GOOGL
Alphabet
EU
PX1
CAC 40
NASDAQ
AAPL
Apple
EU
GLE
Societe Generale
EU
BNP
BNP Paribas
NASDAQ
MSFT
Microsoft
EU
LR
Legrand
EU
VIV
Vivendi
EU
HO
Thales
EU
EN
Bouygues
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés